AI use case

AstraZeneca $200 Million AI Cancer Pact with Tempus and Pathos

Enterprise AI deployment using machine learning and data analytics to automate processes, extract actionable insights from complex data, and improve operational efficiency acros…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: AstraZeneca
Industry: Pharmaceuticals
Location: Cambridge

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

AstraZeneca $200 Million AI Cancer Pact with Tempus and Pathos

Content

Pathos AI Signs Strategic Agreements with AstraZeneca and Tempus for Oncology Foundation Model Pathos AI has announced strategic partnerships with pharmaceutical giant AstraZeneca and healthcare technology company Tempus to develop what will be the largest multimodal foundation model in oncology. Partnership Overview: The agreements bring together three key players in healthcare AI: Pathos AI: Contributing its expertise in AI model development and biomedical research AstraZeneca: Providing pharmaceutical industry knowledge, drug development expertise, and access to clinical data Tempus: Contributing its large-scale clinical data platform and genomic sequencing capabilities Foundation Model for Oncology: The planned multimodal foundation model will integrate genomic data from tumor sequencing, clinical notes and pathology reports, medical imaging, treatment outcomes, and scientific literature. This comprehensive approach aims to accelerate drug discovery, improve patient stratification for clinical trials, and develop more personalized treatment recommendations.

URL

https://www.pathos.com/pathos-signs-strategic-agreements-with-astrazeneca-and-tempus-to-develop-the-largest-multimodal-foundation-model-in-oncology

Continue exploring AI deployments in the catalog.

Back to use cases